Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 8, 2010, Pages 2520-2524

  Evindar, Ghotas ^a   Bernier, Sylvie G ^a   Doyle, Elisabeth ^a   Kavarana, Malcolm J ^a   Satz, Alexander L ^a   Lorusso, Jeanine ^a   Blanchette, Heather S ^a   Saha, Ashis K ^a   Hannig, Gerhard ^a   Morgan, Barry A ^a   Westlin, William F ^a  

^a Praecis Pharmaceuticals Incorporated   (United States)

Author keywords

Immunosuppressants; Lymphopenia; Phenylamide; Phenylimidazole; S1P1 agonists; Sphingosine 1 phosphate (S1P) agonist

Indexed keywords

AMINOALCOHOL; ANILIDE; IMIDAZOLE DERIVATIVE; PPI 4955; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; IN VIVO STUDY; MOUSE; NONHUMAN; PHARMACODYNAMICS; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; AMINO ALCOHOLS; ANIMALS; MICE; RECEPTORS, LYSOSPHINGOLIPID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77950058637     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.02.098     Document Type: Article

References (12)

1. Sugiyama A., Yatomi Y., Ozaki Y., and Hashimoto K. Cardiovasc. Res. 46 (2000) 119
2. Brinkmann V., Davis M.D., Heise C.E., Albert R., Cottens S., Hof R., Bruns C., Prieschl E., Baumruker T., Hiestand P., Foster C.A., Zollinger M., and Lynch K.R. J. Biol. Chem. 277 (2002) 21453
3. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., Thornton R., Shei G.-J., Card D., Keohane C.A., Rosenbach M., Hale J., Lynch C.L., Rupprecht K., Parsons W., and Rosen H. Science 296 (2002) 346
4. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., Allende M.L., Proia R.L., and Cyster J.G. Nature 427 (2004) 355
5. Goetzl E.J., and Graler M.H. J. Leukocyte Biol. 76 (2004) 30
6. Young N., and Van Brocklyn J.R. Scientific World J. 6 (2006) 946
7. Cho H., Harrison K., and Kehrl J.H. Curr. Drug Targets-Immune, Endocrine Metab. Disord. 4 (2004) 107
8. Evindar G., Bernier S.G., Kavarana M.J., Doyle E., Lorusso J., Kelley M.S., Halley K., Hutchings A., Wright A.D., Saha A.K., Hannig G., Morgan B.A., and Westlin W.F. Bioorg. Med. Chem. Lett. 19 (2009) 369
9. Evindar G., Satz A.L., Bernier S.G., Kavarana M.J., Doyle E., Lorusso J., Halley K., Hutchings A., Kelley M.S., Wright A.D., Saha A.K., Hannig G., Morgan B.A., and Westlin W.F. Bioorg. Med. Chem. Lett. 19 (2009) 2315
10. Chueh S.-C.J., and Kahan B. Curr. Opin. Org. Transplant. 8 (2003) 288
11. (R)-3-(tert-Butoxycarbonyl)-2,2,4-trimethyloxazolidine-4-carboxylic acid (6) was synthesized from (S)-2-(tert-butoxycarbonylamino)-3-hydroxy-2-methylpropanoic acid in three steps in overall 55-70% yield. For alternative synthesis of (R)-3-(tert-butoxycarbonyl)-2,2,4-trimethyloxazolidine-4-carboxylic acid (6) see: Clemens, J. J.; Davis, M. D.; Lynch, K. R.; Macdonald, T. L. Bioorg. Med. Chem. Lett. 2005, 15, 3568.
12. Davis D.D., Clemens J.J., Macdonald T.L., and Lynch R.K. J. Biol. Chem. 280 (2005) 9833